42 results on '"Langlais, Blake T."'
Search Results
2. Early national trends of lung allograft use during donation after circulatory death heart procurement in the United States
3. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3
4. Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
5. Lung Transplantation for People Living With HIV: Promising Mid-term Outcomes
6. Neuropsychological decline up to 20 years before incident mild cognitive impairment
7. Correction to: Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
8. Chemoimmunotherapy in patients with extensive‐stage small cell lung cancer and a poor performance status
9. Chemoimmunotherapy as The First-Line Treatment for Patients with Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status of 2 or 3
10. Barriers to patient positioning for telephone cardiopulmonary resuscitation in out-of-hospital cardiac arrest
11. Subjective Cognitive Impairment and the Broad Autism Phenotype
12. Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)‐I study
13. Higher Skeletal Muscle Index Is Associated with Improved Overall Survival in Older Patients with Sarcopenia Undergoing Allogeneic Stem Cell Transplant
14. Correction to: Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
15. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
16. Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
17. Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients
18. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
19. Analysis of Free-Text Responses in an International Myeloproliferative Neoplasms Patient Survey to Assess Impact of the COVID-19 Pandemic on Clinical Care
20. Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019
21. The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms
22. Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition
23. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
24. Neuropsychological decline up to 20 years before incident mild cognitive impairment
25. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies
26. Peppermint Oil to Improve Visualization in Screening Colonoscopy: A Randomized Controlled Clinical Trial
27. Tobacco Use in the Myeloproliferative Neoplasms: Patient Behavior, Opinions, and Care
28. Utilization of Patient-Reported Outcomes in Myeloproliferative Neoplasm Clinical Trials Registered at Clinicaltrials.Gov
29. Survey of Integrative Medicine in Myeloproliferative Neoplasms (The SIMM Study-2)
30. Addressing the Adequacy of Current MPN Pain Management Strategies: An International Survey of 502 Patients By the MPN Quality of Life Study Group
31. Reply to Comment on “Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment”
32. Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?
33. P4‐080: SUBJECTIVE COGNITIVE IMPAIRMENT AND THE BROAD AUTISM PHENOTYPE
34. Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment
35. Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype
36. Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?
37. Psychostimulant Use Among Myeloproloferative Neoplasm Patients
38. Nutrition and Supplement Use Characteristics in the Myeloproliferative Neoplasms: Results from the Nutrient Survey
39. Myeloproliferative Neoplasms and Depressive Symptoms, Diagnosis, and Associations
40. Reply to Comment on "Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment".
41. Sleep and Psychiatric Disturbance in Chronic Philadelphia Negative Myeloproliferative Neoplasms
42. Quality of Life and Symptom Burden Among Patients with Myeloproliferative Neoplasms: Do Symptoms Impact Quality of Life?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.